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ABSTRACT
Infections of the central nervous system (CNS)
caused by herpes viruses can result in severe
diseases, often with a fatal outcome. In this study,
the viral load in the cerebrospinal ﬂuid (CSF) of
patients with herpes simplex or varicella-zoster
infections of the CNS was measured using a
quantitative real-time PCR. The results suggest a
high variability in viral load, with relatively mild
disease associated with a high viral load in CSF
and vice versa. Determination of the viral load in
CSF does not therefore seem to be useful in
assessing the prognosis of disease caused by these
viruses.
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Herpes simplex encephalitis (HSE) is an extreme-
ly dangerous infection of the central nervous
system (CNS), representing the commonest form
of fatal sporadic encephalitis in humans. Most
cases of HSE in adults are associated with herpes
simplex virus type 1 (HSV-1), as are infections of
neonates in Europe [1]; in contrast, neonatal
infections are more frequently caused by herpes
simplex virus type 2 (HSV-2) in America [2].
Neonatal infections are transmitted from an
infected mother, usually during delivery, but
rarely trans-placentally during pregnancy, and
are often devastating to the infant [3]. Varicella-
zoster virus (VZV) causes varicella (chicken-pox)
and herpes zoster (shingles) in humans. Infections
of the CNS caused by VZV can also lead to severe
neurological diseases, e.g., encephalitis, meningo-
encephalitis, meningitis motor paralysis, and
cerebellar ataxia. [4].
Examination of cerebrospinal ﬂuid (CSF) is
important in the diagnosis of CNS infections
caused by HSV and VZV. In particular, molecular
detection of HSV and VZV DNA in CSF speci-
mens is a standard method for diagnosing infec-
tions of the CNS caused by these viruses. In 95%
of cases, viral DNA can be detected during the
ﬁrst week of the clinical disease [5,6]. Real-time
PCR makes it possible to quantify the copies of
speciﬁc nucleic acids present in samples, and it
has been assumed that quantiﬁcation of viral
nucleic acid may be useful in monitoring the
effectiveness of antiviral therapy, and for estab-
lishing the prognosis of the disease. Domingues
et al. [7] examined the potential utility of quanti-
fying HSV DNA in CSF from HSE patients as a
possible prognostic marker [7], and Kimura et al.
[8] considered that quantiﬁcation of the viral load
in serum is useful for assessing the prognosis of
neonatal HSV infections. However, it is not clear
whether quantifying the viral load in CSF
could help to predict the course and severity of
disease.
In the present study, CSF from 120 patients with
symptomatic CNS infections was investigated for
the presence of HSV or VZV DNA using conven-
tional nested PCR [9,10]. The CSF samples were
collected soon after the occurrence of the ﬁrst
neurological symptoms in the ﬁrst phase of clinical
CNS infection, immediately after HSV or VZV
encephalitis was suspected. None of the patients
had been treated with acyclovir or had an immune
deﬁciency. Viral nucleic acid was extracted from
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200 lLofCSFusing aHighPureViralNucleicAcid
Kit (Roche Diagnostics, Mannheim, Germany)
according to the manufacturer’s instructions.
Overall, 31 patients were HSV- or VZV-positive
(Table 1), with ages that ranged from 1 to 53 years
(mean 24 years) for HSV infections, and from 21 to
88 years (mean 56 years) for VZV infections. One
child with varicella as well as neurological disease
was included in the study.
The patients were divided retrospectively into
two groups, according to the progression of the
disease (‘mild’, successful uncomplicated therapy
with good outcome; or ‘severe’, severe course
accompanied by acute neurological signs). After
conﬁrmation of HSV or VZV CNS infection by
PCR, all the patients were treated with acyclovir
(30 mg ⁄kg body weight ⁄day) within 3–4 h of the
PCR analysis.
HSV viral load was measured using a
LightCycler HSV1 ⁄ 2 Detection Kit (Roche Diag-
nostics), adapted according to the quantiﬁcation
values calculated from a calibration curve derived
from the serially diluted LightCycler HSV1 ⁄ 2
Positive Control contained in the kit. VZV-
positive samples were analysed using an Artus
VZV LC PCR Kit (Qiagen, Hamburg, Germany).
The Mann–Whitney U-test was used to compare
the viral load in the specimens and the clinical
differences between the groups, with p <0.05
considered to be signiﬁcant.
In one case, the course of the HSV infection was
extremely severe; despite intensive antiviral
therapy, the infection led to severe neurological
damage. The CSF specimen from this patient
contained virus culturable in human diploid
ﬁbroblasts. Two patients with HSV infection also
had local skin lesions. None of the patients died
during the observation period, but four patients
had permanent severe neurological impairment.
The viral load was highest (1 · 106 copies ⁄mL) in
the patient with an extremely severe course,
associated with extensive damage to the CNS.
However, the viral load in other samples did not
correspond to the clinical course of the infection.
Some patients with relatively mild disease had
high viral loads in their CSF (1 · 104 to
1 · 105 copies ⁄mL), while the viral load for one
patient with a severe outcome was only on the
threshold of detection (3 · 101 copies ⁄mL). There
was no signiﬁcant difference in the outcome of
Table 1. Clinical parameters and viral loads determined using quantitative real-time PCR in patients with central nervous
system infections caused by herpes simplex virus (HSV) or varicella-zoster virus (VZV)
Case no. Age (years) Gender Virus Viral load (copies/mL)
Glasgow coma
scale at administration
of acyclovir Outcome
1 30 F HSV-1 2.2 · 101 14 Good (complete recovery)
2 18 F HSV-1 6.6 · 101 13 Good (complete recovery)
3 79 M HSV-1 7.3 · 101 11 Good (complete recovery)
4 62 F HSV-2 6.2 · 103 14 Poor (severe sequelae)
5 21 F HSV-2 2.2 · 101 13 Poor (severe sequelae)
6 2 M HSV-2 1.0 · 105 5 Poor (very severe sequelae)
7 1 M HSV-1 1.0 · 106 7 Poor (very severe sequelae)
8 23 F HSV-2 1.0 · 105 14 Good (complete recovery)
9 1 M HSV-2 6.8 · 104 13 Good (complete recovery)
10 47 F HSV-1 1.0 · 105 13 Poor (severe sequelae)
11 1 F HSV-1 3.3 · 101 15 Good (complete recovery)
12 53 F HSV-2 2.6 · 101 12 Poor (severe sequelae)
13 1 F HSV-1 1.0 · 104 13 Poor (severe sequelae)
14 1 M HSV-1 2.6 · 104 15 Good (complete recovery)
15 47 M VZV 5.0 · 104 13 Poor (severe sequelae)
16 88 F VZV 6.9 · 102 11 Poor (severe sequelae)
17 31 F VZV 5.7 · 102 11 Poor (severe sequelae)
18 71 M VZV 1.6 · 103 12 Poor (severe sequelae)
19 32 M VZV 6.3 · 103 14 Good (complete recovery)
20 73 M VZV 1.1 · 104 13 Good (complete recovery)
21 68 M VZV 6.2 · 103 13 Good (complete recovery)
22 60 F VZV 1.2 · 103 14 Good (complete recovery)
23 21 M VZV 2.2 · 104 15 Good (complete recovery)
24 43 M VZV 1.8 · 104 14 Good (complete recovery)
25 55 F VZV 5.4 · 102 12 Good (complete recovery)
26 72 M VZV 6.8 · 102 12 Good (complete recovery)
27 6 M VZV 9.1 · 101 15 Good (complete recovery)
28 44 F VZV 2.5 · 103 13 Good (complete recovery)
29 83 M VZV 1.1 · 102 12 Good (complete recovery)
30 86 M VZV 8.3 · 103 13 Good (complete recovery)
31 21 M VZV 1.8 · 104 11 Poor (severe sequelae)
F, female; M, male.
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patients infected with HSV-1 and those infected
with HSV-2. Patients with VZV-positive CSF had
clinical signs of meningeal irritation and biochem-
ical markers of neuroinfection in CSF, accompa-
nied by clinical herpes zoster and, in one case, by
varicella.
VZV DNAwas detected in 17 CSF samples from
16 patients with herpes zoster, and in one sample
from a child with varicella, complicated by men-
ingitis. TheVZV load inCSF ranged from1 · 102 to
5 · 104 copies ⁄mL. The highest virus loads
(5 · 104 and 2 · 104 copies ⁄mL) were detected in
a patient with paresis of the facial nerve and a
young patient with relatively mild disease.
The lowest virus load (1 · 102 copies ⁄mL) was
detected in a child with varicella meningitis
and in an elderly patient with severe CNS
infection accompanied by herpes zoster of the
trunk.
It was concluded that there is considerable
variability in HSV and VZV viral loads in CSF
samples, with no signiﬁcant correlation between
the viral load and the outcome (Table 1). Domi-
nigues et al. [7] found that patients with >100 cop-
ies of HSV DNA ⁄ lL of CSF had a less successful
outcome than those with <100 copies, suggesting
the possible value of quantitative measurement of
HSV copies in CSF for disease prognosis. In
contrast, Lakeman et al. [6] failed to ﬁnd a
correlation between the detection of HSV DNA
in CSF and clinical and laboratory ﬁndings [6]. In
agreement with the present study, Wildemann
et al. [11] found that the viral load in CSF did not
correlate with the severity of clinical signs or the
degree of the cranial imaging ﬁndings and the
outcome of HSE. Similarly, Kamei et al. [12]
demonstrated that initial and maximum viral
loads, evaluated by the chemiluminiscence assay
for antigen and nested PCR, showed a wide
distribution in CSF from patients with poor or
good outcomes [12]. The absence of a clear
correlation between viral load in CSF and out-
come suggests a role for indirect mechanisms of
brain injury in HSE [11], and immune cytokine
responses associated with HSE may play a sig-
niﬁcant role in the outcome of the infection [12].
Based on these results, quantitative analysis of
HSV and VZV in CSF is more suitable for
monitoring the progress of the disease and the
effectiveness of antiviral therapy than for estab-
lishing the prognosis.
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